Applied Molecular "announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naive and experienced patients with moderate-to-severe ulcerative colitis. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule. The clinical remission rate in patients treated with AMT-101 monotherapy was 17.1% compared to a CR rate of 20.0% with placebo, which was above the company’s baseline assumption for placebo CR rates based on published data in moderate-to-severe UC patients."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMTI:
- Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport initiated with a Buy at Chardan
- Applied Molecular Transport announces FDA ODD granted to AMT-101
- Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis
- Applied Molecular Transport to Present at Upcoming November Investor Conferences